Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Verschueren

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Rheumatology (Oxford, England)|October 12, 2015
Should rheumatoid arthritis patients preferentially be treated with tocilizumab after rituximab failure?Patrick Verschueren
Nature Reviews. Rheumatology|July 4, 2012
Rheumatoid arthritis: defining remission in patients with RA in clinical practiceRene Westhovens, Patrick Verschueren
Arthritis Research & Therapy|November 26, 2008
Translating co-stimulation blockade into clinical practiceRene Westhovens, Patrick Verschueren
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
The efficacy and safety of abatacept in rheumatoid arthritisRene Westhovens, Patrick Verschueren
Annals of the Rheumatic Diseases|October 30, 2023
Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023René Westhovens, Patrick Verschueren
Rheumatology (Oxford, England)|April 2, 2011
Optimal care for early RA patients: the challenge of translating scientific data into clinical practicePatrick Verschueren, René Westhovens
Rheumatology (Oxford, England)|October 3, 2017
The use of glucocorticoids in early rheumatoid arthritisPatrick Verschueren, Rene Westhovens
Rheumatology (Oxford, England)|March 21, 2019
Primus inter pares: the choice of biologic drugs in rheumatoid arthritisDiederik De Cock, Patrick Verschueren
RMD Open|January 29, 2022
JAK inhibition and the holy grail for pain control in early RASofia Pazmino, Patrick Verschueren, René Westhovens
Rheumatology (Oxford, England)|March 29, 2026
Predicting DMARD tapering success in rheumatoid arthritis: are we considering what matters to patients?Rene Westhovens, Michaël Doumen, Patrick Verschueren
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Rheumatology (Oxford, England)|October 12, 2015
Should rheumatoid arthritis patients preferentially be treated with tocilizumab after rituximab failure?Patrick Verschueren
Nature Reviews. Rheumatology|July 4, 2012
Rheumatoid arthritis: defining remission in patients with RA in clinical practiceRene Westhovens, Patrick Verschueren
Arthritis Research & Therapy|November 26, 2008
Translating co-stimulation blockade into clinical practiceRene Westhovens, Patrick Verschueren
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
The efficacy and safety of abatacept in rheumatoid arthritisRene Westhovens, Patrick Verschueren
Annals of the Rheumatic Diseases|October 30, 2023
Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023René Westhovens, Patrick Verschueren
Rheumatology (Oxford, England)|April 2, 2011
Optimal care for early RA patients: the challenge of translating scientific data into clinical practicePatrick Verschueren, René Westhovens
Rheumatology (Oxford, England)|October 3, 2017
The use of glucocorticoids in early rheumatoid arthritisPatrick Verschueren, Rene Westhovens
Rheumatology (Oxford, England)|March 21, 2019
Primus inter pares: the choice of biologic drugs in rheumatoid arthritisDiederik De Cock, Patrick Verschueren
RMD Open|January 29, 2022
JAK inhibition and the holy grail for pain control in early RASofia Pazmino, Patrick Verschueren, René Westhovens
Rheumatology (Oxford, England)|March 29, 2026
Predicting DMARD tapering success in rheumatoid arthritis: are we considering what matters to patients?Rene Westhovens, Michaël Doumen, Patrick Verschueren
Pageof 16